Explanatory Memorandum to COM(2015)674 - Subjecting the new psychoactive substance 1-phenyl-2-(1-pyrrolidin-1-yl) pentan-1-one (α-pyrrolidinovalerophenone, α-PVP) to control measures - Main contents
Please note
This page contains a limited version of this dossier in the EU Monitor.
| dossier | COM(2015)674 - Subjecting the new psychoactive substance 1-phenyl-2-(1-pyrrolidin-1-yl) pentan-1-one (α-pyrrolidinovalerophenone, ... |
|---|---|
| source | COM(2015)674  |
| date | 18-12-2015 |
1. CONTEXT OF THE PROPOSAL
Council Decision 2005/387/JHA on the information exchange, risk-assessment and control of new psychoactive substances 1 provides for a three-step procedure that may lead to the submission of a new psychoactive substance to control measures across the Union.
On 3 August 2015, a joint report of the European Monitoring Centre for Drugs and Drug Addition (EMCDAA) and Europol drawn up in accordance with Article 5 of Council Decision 2005/387/JHA was issued. On 15 September 2015, following the request made by the Commission and seventeen Member States and pursuant to Article 6(1) of the above-mentioned Council Decision, the Council requested an assessment of the risks caused by the use, manufacture and trafficking of the new psychoactive substance α-PVP, the involvement of organised crime and the possible consequences of control measures introduced on this substance.
The risks of α-PVP were assessed by the Scientific Committee of the EMCDDA, acting in compliance with the provisions of Article 6(2), (3) and i of the Council Decision. The Chair of the Scientific Committee submitted the risk assessment report to the Commission and to the Council on 27 November 2015. The main results of the risk assessment are the following:
α-PVP is a potent psychostimulant. The substance detected in all 28 Member States as well as in Turkey and Norway, is mainly imported into the EU drug market from China and then distributed across Europe.
There have been a total of 115 deaths and 191 acute intoxications registered in eight Member States reported where α-PVP was detected.
There are no available information or published studies assessing in a comprehensive way the health risks associated with α-PVP, namely chronic and acute toxicity, but observations in animals suggest similar effects with those observed with other stimulants.
Pursuant to Article 8(1) of Council Decision 2005/387/JHA, within six weeks from the date of receipt of the risk assessment report, the Commission shall present to the Council either an initiative to subject the new psychoactive substances to control measures across the Union, or a report explaining its views on why such an initiative is not deemed necessary. According to the judgement of the Court of Justice of 16 April 2015 in Joined Cases C-317/13 and C-679/13 the European Parliament must be consulted before an act based on Article 8(1) of Council Decision 2005/387/JHA is adopted.
Based on the findings of the risk assessment report the Commission considers that there are grounds for subjecting this substance to control measures across the Union. According to the risk assessment report, the acute toxicity of α-PVP is such that it can cause severe harms to the health of individuals.
2. OBJECTIVE OF THE PROPOSAL
The objective of this proposal for a Council Decision is to call upon the Member States to subject α-PVP to control measures and criminal penalties as provided under their legislation by virtue of their obligations under the 1971 United Nations Convention on Psychotropic Substances.